Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1b study to determine safety of ramucirumab administered in combination with erlotinib or osimertinib for patients with untreated EGFR-mutated non–small cell lung cancer and asymptomatic brain metastases

Next Previous
X
Search
Trial Profile

A phase 1b study to determine safety of ramucirumab administered in combination with erlotinib or osimertinib for patients with untreated EGFR-mutated non–small cell lung cancer and asymptomatic brain metastases

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ramucirumab (Primary) ; Erlotinib; Osimertinib
  • Indications Brain metastases; Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms RELAY-Brain

    • Most Recent Events

    • 08 Jul 2021 New trial record
    • 02 Jul 2021 Results of analysis assessing DLT, safety and treatment exposure (median follow-up 9.4months) published in the Investigational New Drugs

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top